Potent Inducers of Endogenous Antimicrobial Peptides for Host Directed Therapy of Infections.
Ottosson. H H; Nylén. F F; Sarker. P P; Miraglia. E E; Bergman. P P; Gudmundsson. G H GH; Raqib. R R; Agerberth. B B; Strömberg. R R
Key Findings
- APDs can induce a 20‑30‑fold increase in LL‑37 production in human cells in vitro.
- Oral administration of an APD helped rabbits recover quickly from Shigellosis, an intestinal infection.
Practical Outcomes
- For biohackers, the idea of boosting LL‑37 with a small molecule is intriguing, but APDs are not yet commercially available and safety data in humans are lacking. Until more research and human trials are done, the finding serves more as a concept to watch rather than a ready‑to‑use protocol. Enthusiasts might monitor future studies for potential supplement or drug candidates that safely raise LL‑37 levels.
Summary
Scientists found a new class of compounds called aroylated phenylenediamines (APDs) that can make our bodies produce a lot more of the natural antimicrobial peptide LL‑37 – up to 20‑30 times more in lab tests. When one of these compounds was given by mouth to rabbits with a severe gut infection, the animals got better in just a few days, suggesting the approach could help fight infections by boosting our own defenses.
Abstract
A new concept for treatment of infections is induction of our own antimicrobial peptides and the presented novel class of inducer, aroylated phenylenediamines (APDs), gives up to 20 to 30-fold induction of the human antimicrobial peptide LL-37, in vitro. In addition, oral administration of an APD in a rabbit model of Shigellosis resulted in recovery from the infection in a few days implying that APD's are promising candidates for treatment of infections.
Study Information
pubmed
2016
2016-11-09T00:00:00.000Z
10.1038/srep36692
38
39